ArticleThe Korean journal of internal medicine2025
Impact of body mass index on clinical outcomes in intestinal Behçet's disease.
Article in The Korean journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence of frailty and its association with quality of life in Japanese patients with Behçet's disease.Clinical rheumatology · 2026Article
- Association between body mass index and palindromic rheumatism risk and outcomes: a case-control study.Clinical rheumatology · 2026Article
- Successful upadacitinib treatment in anti-TNF-refractory intestinal Behçet's disease: a case report and literature review.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe impact of body mass index (BMI) on the clinical outcomes of intestinal Behçet's disease (BD) remains unclear. This study assessed the association between BMI and disease progression.
methodsA retrospective analysis of 760 patients with intestinal BD was conducted. Patients were classified by BMI as underweight (< 18.5 kg/m2), normal (18.5-22.9), overweight (23.0-24.9), or obese (≥ 25.0). The association between BMI and clinical outcomes-biologics, surgery, hospitalization, and emergency visits-was examined.
resultsAmong 760 patients, 130 (17.1%) were underweight, 384 (50.5%) normal, 152 (20.0%) overweight, and 94 (12.4%) obese. Higher BMI linked to lower cumulative rates of biologics use (p trend = 0.002), surgery (p trend = 0.004), hospitalization (p trend = 0.004), and emergency visits (p trend = 0.008). Compared with the underweight group, the normal (HR 0.667, 95% CI 0.483-0.922, p = 0.014), overweight (HR 0.589, 95% CI 0.394-0.879, p = 0.010), and obese groups (HR 0.515, 95% CI 0.321-0.828, p = 0.006) had lower hospitalization risks. The overweight (HR 0.490, 95% CI 0.241-0.996, p = 0.049) and obese (HR 0.312, 95% CI 0.116-0.840, p = 0.021) groups were negatively associated with future biologics use. The normal (HR 0.705, 95% CI 0.480-1.036, p = 0.075) and obese (HR 0.510, 95% CI 0.272-0.953, p = 0.035) groups were negatively associated with future surgery in multivariable analysis.
conclusionLower BMI was linked to poorer clinical outcomes in intestinal BD, emphasizing the need to optimize nutritional status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.